Diabetic Autonomic Neuropathy disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: DBT002 MIFTS: 41	Diabetic Autonomic Neuropathy Categories: Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Diabetic Autonomic Neuropathy

MalaCards integrated aliases for Diabetic Autonomic Neuropathy:

Name: Diabetic Autonomic Neuropathy ¹² ⁵⁴ ¹⁵ ⁷¹

Diabetic Neuropathies ⁴³ ⁷¹

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:11503

MeSH ⁴³ D003929

NCIt ⁴⁹ C27068

SNOMED-CT ⁶⁷ 50620007

UMLS ⁷¹ C0011882 C0271686

Sources

Summaries for Diabetic Autonomic Neuropathy

MalaCards based summary : Diabetic Autonomic Neuropathy, also known as diabetic neuropathies, is related to microvascular complications of diabetes 1 and microvascular complications of diabetes 5, and has symptoms including sciatica and neuralgia. An important gene associated with Diabetic Autonomic Neuropathy is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways/superpathways are p70S6K Signaling and Peptide hormone metabolism. The drugs Quinapril and Bromocriptine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and spinal cord.

Sources

Related Diseases for Diabetic Autonomic Neuropathy

Diseases related to Diabetic Autonomic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 374)

#	Related Disease	Score	Top Affiliating Genes
1	microvascular complications of diabetes 1	33.1	NTF3 NGF INS AKR1B1
2	microvascular complications of diabetes 5	32.2	INS AKR1B1 ACE
3	gastroparesis	30.7	MLNR MLN GAST
4	pure autonomic failure	30.5	REN EPO ACE
5	iritis	30.4	EPO ACE
6	neurogenic arthropathy	30.3	NGF INS
7	silent myocardial infarction	30.3	INS ACE
8	algoneurodystrophy	30.2	NGF INS
9	peptic esophagitis	30.1	MLN GAST
10	diabetic encephalopathy	30.1	NGF INS
11	pylorospasm	30.1	MLNR MLN
12	duodenal ulcer	30.0	MLN INS GAST
13	sensory peripheral neuropathy	30.0	NTF3 NGF AKR1B1
14	diabetic polyneuropathy	29.8	NTF3 NGF INS AKR1B1
15	polyneuropathy	29.8	NGF INS EPO AKR1B1 ACE
16	anorexia nervosa	29.7	PPY INS GCG
17	hypertension, diastolic	29.7	REN ACE
18	vascular disease	29.7	REN INS EPO ACE
19	peripheral vascular disease	29.6	INS GAST EPO ACE
20	sleep apnea	29.6	REN INS EPO ACE
21	microvascular complications of diabetes 3	29.5	REN INS AKR1B1 ACE
22	sleep disorder	29.4	REN INS ACE
23	diarrhea	29.3	SI REN MLN GAST
24	uremia	29.3	REN INS EPO ACE
25	nasopharyngitis	29.3	SI INS GCG
26	diabetes mellitus, ketosis-prone	29.3	SI INS GCG
27	end stage renal disease	29.3	REN INS EPO ACE
28	carbohydrate metabolic disorder	29.2	SI INS GCG
29	diabetic neuropathy	29.2	REN NTF3 NGF INS EPO AKR1B1
30	constipation	29.1	NTF3 MLNR MLN INS GCG GAST
31	apnea, obstructive sleep	28.9	REN INS GCG ACE
32	autonomic neuropathy	28.9	REN PPY NTF3 NGF MLNR MLN
33	congestive heart failure	28.9	REN INS EPO ACE
34	anuria	28.9	REN ACE
35	prediabetes syndrome	28.9	SI INS GCG ACE
36	orthostatic intolerance	28.9	REN EPO ADAM8 ACE
37	chronic kidney disease	28.8	REN INS EPO ACE
38	pheochromocytoma	28.7	REN NGF MLN EPO ACE
39	kidney disease	28.7	REN INS GCG EPO AKR1B1 ACE
40	diabetes mellitus	28.6	REN MLN INS GCG EPO AKR1B1
41	body mass index quantitative trait locus 11	28.3	REN MLN INS GCG AKR1B1 ACE
42	diabetes mellitus, type i	28.1	SI REN PPY INS GCG AKR1B1
43	peripheral nervous system disease	27.9	SI REN NTF3 NGF INS GCG
44	diabetes mellitus, noninsulin-dependent	27.4	SI REN PPY NGF INS GCG
45	microvascular complications of diabetes 2	11.4
46	neuropathy	11.2
47	abducens nerve disease	11.1
48	argyll robertson pupil	11.1
49	fainting	11.1
50	syncope	11.1

Graphical network of the top 20 diseases related to Diabetic Autonomic Neuropathy:

Sources

Symptoms & Phenotypes for Diabetic Autonomic Neuropathy

UMLS symptoms related to Diabetic Autonomic Neuropathy:

sciatica, neuralgia

Sources

Drugs & Therapeutics for Diabetic Autonomic Neuropathy

Drugs for Diabetic Autonomic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 236)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Quinapril

Approved, Investigational

Phase 4

85441-61-8

54892

Bromocriptine

Approved, Investigational

Phase 4

25614-03-3

31101

tannic acid

Approved

Phase 4

1401-55-4

Benzocaine

Approved, Investigational

Phase 4

94-09-7, 1994-09-7

2337

Methylcobalamin

Approved, Investigational

Phase 4

13422-55-4

Hydroxocobalamin

Approved

Phase 4

13422-51-0

15589840 11953898

Acetylcholine

Approved, Investigational

Phase 4

51-84-3

187

Capsaicin

Approved

Phase 4

404-86-4

1548943

Nabilone

Approved, Investigational

Phase 4

51022-71-0

5284592

Amitriptyline

Approved

Phase 4

50-48-6

2160

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Histamine

Approved, Investigational

Phase 4

51-45-6

774

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

leucovorin

Approved

Phase 4

58-05-9

6006 143

Acetaminophen

Approved

Phase 4

103-90-2

1983

Cetirizine

Approved

Phase 4

83881-51-0

2678

Gabapentin

Approved, Investigational

Phase 4

60142-96-3

3446

Donepezil

Approved

Phase 4

120014-06-4

3152

Ranolazine

Approved, Investigational

Phase 4

142387-99-3, 95635-55-5

56959

Cyanocobalamin

Approved, Nutraceutical

Phase 4

68-19-9

44176380

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Pyridoxine

Approved, Investigational, Nutraceutical, Vet_approved

Phase 4

65-23-6

1054

Pyridoxal Phosphate

Approved, Investigational, Nutraceutical

Phase 4

54-47-7

1051

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4

1406-16-2

Cobalamin

Experimental

Phase 4

13408-78-1

6857388

protease inhibitors

Phase 4

HIV Protease Inhibitors

Phase 4

Antioxidants

Phase 4

Protective Agents

Phase 4

Antimetabolites

Phase 4

Dopamine agonists

Phase 4

Alpha-lipoic Acid

Phase 4

Thioctic Acid

Phase 4

Vitamin B 12

Phase 4

Vitamin B12

Phase 4

Vasodilator Agents

Phase 4

Anesthetics

Phase 4

Anesthetics, Local

Phase 4

Amitriptyline, perphenazine drug combination

Phase 4

Anti-Arrhythmia Agents

Phase 4

Histamine Antagonists

Phase 4

Anti-Allergic Agents

Phase 4

Histamine H1 Antagonists

Phase 4

Histamine Phosphate

Phase 4

51-74-1

65513

Hypolipidemic Agents

Phase 4

Anticholesteremic Agents

Phase 4

Lipid Regulating Agents

Phase 4

Citrate

Phase 4

Vitamin B 6

Phase 4

Analgesics, Non-Narcotic

Phase 4

Interventional clinical trials:

(show top 50) (show all 394)

#	Name	Status	NCT ID	Phase	Drugs
1	Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial	Unknown status	NCT00752440	Phase 4
2	Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial	Unknown status	NCT00123136	Phase 4
3	Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN)	Unknown status	NCT01770964	Phase 4	Pregabalin;placebo
4	Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus	Completed	NCT03031834	Phase 4	Quinapril
5	Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects	Completed	NCT02682901	Phase 4	Cycloset;Placebo
6	Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain	Completed	NCT00322621	Phase 4	Duloxetine
7	A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy	Completed	NCT00380913	Phase 4	Cesamet™ (nabilone)
8	An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy	Completed	NCT00644748	Phase 4	gabapentin
9	A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain	Completed	NCT02417935	Phase 4	Duloxetine;Pregabalin;Placebo
10	An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy	Completed	NCT00159731	Phase 4	Pregabalin
11	A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).	Completed	NCT00156078	Phase 4	pregabalin
12	A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain	Completed	NCT00266643	Phase 4	duloxetine hydrochloride
13	An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain	Completed	NCT00385671	Phase 4	duloxetine hydrochloride;pregabalin;gabapentin
14	A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy	Completed	NCT00159679	Phase 4	Pregabalin
15	Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies	Completed	NCT02842554	Phase 4	Drug Placebo Administration
16	Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia	Completed	NCT00629681	Phase 4	Pregabalin
17	A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)	Completed	NCT00726713	Phase 4
18	A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain	Completed	NCT00904020	Phase 4	Lidoderm
19	Bone Marrow Responsiveness to Pharmacologic Mobilization of Progenitor Cells in Diabetic Versus Non-diabetic Patients	Completed	NCT01102699	Phase 4	Filgrastim, hrG-CSF
20	A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy	Completed	NCT03914404	Phase 4	γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
21	Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy	Completed	NCT02891928	Phase 4
22	The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Patients With Diabetic Peripheral Neuropathic Pain: a Randomized, Placebo-controlled Study of South Asian Male Patients	Completed	NCT04238208	Phase 4	Lidocaine 5% patch;Capsaicin 8% Patch, Per 10 Square Centimeters
23	A Randomised, Controlled, Cross-over Study With Inpatient and Outpatient Phases	Completed	NCT01352767	Phase 4
24	Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain	Completed	NCT01251211	Phase 4	botulinum toxin type A
25	A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy	Completed	NCT00120341	Phase 4
26	A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study	Completed	NCT00614341	Phase 4
27	Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain	Completed	NCT01364298	Phase 4	Gabapentin/B-complex;Pregabalin
28	A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy	Completed	NCT00573261	Phase 4	Pregabalin;Placebo
29	An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)	Completed	NCT00194909	Phase 4	sildenafil (Viagra)
30	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions	Completed	NCT00904202	Phase 4	Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
31	Gabapentin Kinetic Disposition and Renal Excretion: Role of Transporters for Organic Cations and the Effect of Glycemic Control in Patients With Neuropathic Pain.	Completed	NCT03047278	Phase 4	Gabapentin 300 mg;Cetirizine Hydrochloride 10 mg
32	A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD	Completed	NCT00844194	Phase 4	Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
33	High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy	Completed	NCT04377399	Phase 4	Vitamin D
34	Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy	Completed	NCT01628627	Phase 4
35	The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes	Completed	NCT00931879	Phase 4	omega-3-ethyl esters;Placebo
36	Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study	Completed	NCT00634543	Phase 4	Tramadol hydrochloride/ Acetaminophen;Gabapentin
37	Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading	Completed	NCT02439879	Phase 4	Alpha lipoic acid
38	PRELIMINARY EVALUATION OF RETINAL EFFECTS OF PHARMACOLOLOGICAL LOWERING OF SERUM LEVES OF ADVANCED GLYCATION END-PRODUCTS (AGEs) IN TYPE 2 DIABETIC PATIENTS	Completed	NCT02249897	Phase 4	CHOLESTYRAMINE
39	RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy	Recruiting	NCT02586623	Phase 4	Droxidopa capsules;Placebo capsules
40	Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM)	Recruiting	NCT04246619	Phase 4	Pregabalin;Duloxetine
41	Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes	Not yet recruiting	NCT04193566	Phase 4	Forxiga
42	Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy	Terminated	NCT00619983	Phase 4	donepezil;duloxetine;donepezil 2.5 mg and duloxetine 30mg;placebo;gabapentin
43	A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP)	Terminated	NCT02156336	Phase 4	Ranolazine;Placebo
44	Precision Spinal Cord Stimulation for Painful Diabetic Neuropathy	Terminated	NCT00487981	Phase 4
45	Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin: a Randomized Controlled Flexible-dose Study in Patients With Neuropathic Pain	Withdrawn	NCT01116531	Phase 4	Tramadol;Duloxetine;Pregabalin
46	A Double-blind, Randomized, Parallel 2- Arm Study to Compare the Efficacy of Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes Who Are Receiving Background Standard-of-care Cardio-metabolic Therapy With Metformin, an Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker, and a Statin.	Withdrawn	NCT03640221	Phase 4	Ertugliflozin;Hydrochlorothiazide 12.5mg
47	Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)and Diabetic Neuropathy in Subjects With Sensorimotor Diabetic Polyneuropathy: a Double-blind, Randomized, Placebo-controlled Parallel Group Pilot Study Over 12 Months.	Unknown status	NCT01868191	Phase 3	Benfotiamine;Placebo for benfotiamine
48	Diabetic Neuropathic Pain Topical Treatment- Comparative Study	Unknown status	NCT00661063	Phase 3	ketamine;vehicle gel;ketamine + clonidine;clonidine gel 1%
49	Study of Topical Preparation of Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy	Unknown status	NCT01125215	Phase 2, Phase 3	0.75% capsaicin nanoparticle cream;Placebo
50	A Randomized, Sham-Controlled Clinical Study to Evaluate The Effect of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy	Unknown status	NCT00134524	Phase 3

Search NIH Clinical Center for Diabetic Autonomic Neuropathy

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Becaplermin

CAPSACIAN PWDR

Capsaicin

CAPSAICIN PWDR

Capsicum extract

CAPSICUM OLEORESIN

Citalopram

Citalopram hydrobromide

COBALAMIN CONCENTRATE

Hydroxocobalamin

HYDROXOCOBALAMIN ACETATE

mecobalamin

Mexiletine

Mexiletine Hydrochloride

Pentoxifylline

Vitamin B 12

Cochrane evidence based reviews: diabetic neuropathies

Sources

Genetic Tests for Diabetic Autonomic Neuropathy

Sources

Anatomical Context for Diabetic Autonomic Neuropathy

MalaCards organs/tissues related to Diabetic Autonomic Neuropathy:

⁴⁰

Heart, Testes, Spinal Cord, Skin, Bone, Brain, Bone Marrow

Sources

Publications for Diabetic Autonomic Neuropathy

Articles related to Diabetic Autonomic Neuropathy:

(show top 50) (show all 1033)

#	Title	Authors	PMID	Year
1	Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy. ⁶¹ ⁵⁴	Schmidt RE...Escandon E	11245210	2001
2	Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years. ⁵⁴ ⁶¹	Didangelos TP...Kourtoglou GI	9647338	1998
3	Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. ⁶¹ ⁵⁴	Didangelos TP...Kontopoulos AG	18370475	1998
4	An investigation of antibodies to nerve growth factor in diabetic autonomic neuropathy. ⁵⁴ ⁶¹	Zanone MM...Watkins PJ	8088110	1994
5	Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. ⁶¹ ⁵⁴	Erbas T...Akalin S	8299441	1993
6	Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor. ⁵⁴ ⁶¹	Faes TJ...Bertelsmann FW	8482988	1993
7	The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus. ⁶¹ ⁵⁴	Roy TM...Pfeifer MA	2123430	1990
8	Modeling Hypoxia-Induced Neuropathies Using a Fast and Scalable Human Motor Neuron Differentiation System. ⁶¹	Hudish LI...Russ HA	32386561	2020
9	Expression study of candidate miRNAs and evaluation of their potential use as biomarkers of diabetic neuropathy. ⁶¹	Ciccacci C...Borgiani P	32400192	2020
10	Stem Cell Therapies for the Treatment of Diabetic Neuropathies: Future Perspectives. ⁶¹	de Figueiredo CS...Dos Reis LC	32303173	2020
11	Spectrum of diabetic neuropathies. ⁶¹	Sasaki H...Low PA	32206478	2020
12	Assessment of cutaneous axon-reflex responses to evaluate functional integrity of autonomic small nerve fibers. ⁶¹	Hijazi MM...Siepmann T	32125538	2020
13	Clinical Impact of Atypical Chest Pain and Diabetes Mellitus in Patients with Acute Myocardial Infarction from Prospective KAMIR-NIH Registry. ⁶¹	Lee JW...Yoon J	32059609	2020
14	Autonomic Peripheral Neuropathy. ⁶¹	Freeman R	31996622	2020
15	Diabetic autonomic neuropathy of the gastrointestinal tract. ⁶¹	Kuznik E...Poniewierka E	32550939	2020
16	Increased arrhythmia susceptibility in type 2 diabetic mice related to dysregulation of ventricular sympathetic innervation. ⁶¹	Jungen C...Tompkins JD	31625779	2019
17	Commentary: Recognizing pupillary dysfunction in diabetic autonomic neuropathy. ⁶¹	Sudhakar P	31332119	2019
18	Commentary: Abnormal pupillary light reflexes - A sign of diabetic autonomic neuropathy. ⁶¹	Saxena R...Dhiman R	31332118	2019
19	Association of pupil responses with severity of erectile dysfunction in diabetes mellitus. ⁶¹	Cankurtaran V...Ozler S	31332117	2019
20	Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. ⁶¹	Hicks CW...Selvin E	31456118	2019
21	Role of Inflammation in the Pathogenesis of Diabetic Peripheral Neuropathy. ⁶¹	Ristikj-Stomnaroska D...Papazova M	31592273	2019
22	Diabetic neuropathies influence recovery from hip-fracture surgery in older persons with diabetes. ⁶¹	Tseng MY...Shyu YL	30738920	2019
23	Painful and Painless Diabetic Neuropathies: What Is the Difference? ⁶¹	Shillo P...Tesfaye S	31065863	2019
24	Omega-3 polyunsaturated fatty acids exert anti-oxidant effects through the nuclear factor (erythroid-derived 2)-related factor 2 pathway in immortalized mouse Schwann cells. ⁶¹	Tatsumi Y...Kato K	30216708	2019
25	Novel Insights into Sensorimotor and Cardiovascular Autonomic Neuropathy from Recent-Onset Diabetes and Population-Based Cohorts. ⁶¹	Herder C...Ziegler D	30935671	2019
26	Uncoupling neurotrophic function from nociception of nerve growth factor: what can be learned from a rare human disease? ⁶¹	Sung K...Wu C	30632491	2019
27	Suppression Failure of Cortisol Secretion by Dexamethasone May Occur in Glucagon-like Peptide-1 Receptor Agonist-treated Patients with Diabetic Autonomic Neuropathy. ⁶¹	Nagai Y...Shimomura I	30568127	2019
28	Droxidopa for Hypotension of Different Etiologies: Two Case Reports. ⁶¹	Oommen J...Hanna A	30828233	2019
29	Early Alterations of Corneal Subbasal Plexus in Uncomplicated Type 1 Diabetes Patients. ⁶¹	Schiano Lomoriello D...Picconi F	31341662	2019
30	['Point of no return' in diabetic neuropathies: a dangerous delusion]. ⁶¹	Akhmadeeva LR...Yakupov EZ	31626177	2019
31	Diagnostic accuracy of composite autonomic symptom scale 31 (COMPASS-31) in early detection of autonomic dysfunction in type 2 diabetes mellitus. ⁶¹	Singh R...Joshi R	31564941	2019
32	Involvement of P2Y12 receptor of stellate ganglion in diabetic cardiovascular autonomic neuropathy. ⁶¹	Guo J...Li G	30084083	2018
33	Altered pain processing in people with type I and II diabetes: a protocol for a systematic review and meta-analysis of pain threshold and pain modulation mechanisms. ⁶¹	Sierra-Silvestre E...Coppieters MW	30518431	2018
34	Catechin attenuates diabetic autonomic neuropathy in streptozotocin induced diabetic rats. ⁶¹	Addepalli V...Suryavanshi SV	30372853	2018
35	Diabetic autonomic neuropathy resulting in sexual dysfunction. ⁶¹	Wooton AK...Melchior LM	30256272	2018
36	Ethnic variation of IL-4 intron 3 VNTR gene polymorphism; its association with type 2 diabetes mellitus and its complication (neuropathy) in Egyptian subjects. ⁶¹	Ali R...Settin A	30318704	2018
37	The relationship of one-leg standing time with peripheral nerve function and clinical neuropathy in patients with type 2 diabetes. ⁶¹	Sugimoto K...Shimbo T	30603374	2018
38	Effects of whole body vibration in individuals with diabetic peripheral neuropathy: a systematic review. ⁶¹	Robinson CC...Plentz RDM	30179216	2018
39	Inflammatory Diabetic Neuropathy: Helpful Diagnostic Parameters. ⁶¹	Thaisetthawatkul P...Dyck PJB	30124555	2018
40	Autonomic disturbances in diabetes: Assessment and anaesthetic implications. ⁶¹	Moningi S...Ramachandran G	30166651	2018
41	Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice. ⁶¹	Gumuslu E...Ulak G	29091313	2018
42	Diffuse microvascular C5b-9 deposition is a common feature in muscle and nerve biopsies from diabetic patients. ⁶¹	Yell PC...Cai C	29458425	2018
43	Association between a MIR499A polymorphism and diabetic neuropathy in type 2 diabetes. ⁶¹	Ciccacci C...Spallone V	29108839	2018
44	Predictors of Cardiovascular Autonomic Neuropathy Onset and Progression in a Cohort of Type 1 Diabetic Patients. ⁶¹	Matta M...Senard JM	29693021	2018
45	Prevalence of cardiovascular autonomic neuropathy and gastroparesis symptoms among patients with type 2 diabetes who attend a primary health care center. ⁶¹	AlOlaiwi LA...Tourkmani AM	30576362	2018
46	[Diabetic and non-diabetic neuropathies in patients with diabetes mellitus]. ⁶¹	Akhmedzhanova LT...Strokov IA	29863704	2018
47	Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension. ⁶¹	Vernino S...Kremens D	28623420	2017
48	Assessment of diabetic neuropathy with emission tomography and magnetic resonance spectroscopy. ⁶¹	Rao H...Tipre D	28234786	2017
49	Advanced glycation end products induce brain-derived neurotrophic factor release from human platelets through the Src-family kinase activation. ⁶¹	Furukawa K...Takei N	28178976	2017
50	Role of "Sural Sparing" Pattern (Absent/Abnormal Median and Ulnar with Present Sural SNAP) Compared to Absent/Abnormal Median or Ulnar with Normal Sural SNAP in Acute Inflammatory Demyelinating Polyneuropathy. ⁶¹	Surpur SS...Govindarajan R	29085327	2017

Sources

Genes for Diabetic Autonomic Neuropathy

Genes related to Diabetic Autonomic Neuropathy (0 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	AKR1B1	Aldo-Keto Reductase Family 1 Member B	Protein Coding	20.65	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	8482988 2123430 9647338 (more) 18370475
2	MLNR	Motilin Receptor	Protein Coding	19.41	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	8299441
3	INS	Insulin	Protein Coding	13.76	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	GCG	Glucagon	Protein Coding	12.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	EPO	Erythropoietin	Protein Coding	11.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	NTF3	Neurotrophin 3	Protein Coding	11.41	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	MLN	Motilin	Protein Coding	11.08	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	AOC1	Amine Oxidase Copper Containing 1	Protein Coding	10.59	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	NGF	Nerve Growth Factor	Protein Coding	8.67	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	8088110 11245210
10	PPY	Pancreatic Polypeptide	Protein Coding	6.61	DISEASES inferred ¹⁵
11	GAST	Gastrin	Protein Coding	6.37	GeneCards inferred via : Publications (show sections)
12	REN	Renin	Protein Coding	5.73	DISEASES inferred ¹⁵
13	ACE	Angiotensin I Converting Enzyme	Protein Coding	5.73	DISEASES inferred ¹⁵
14	SI	Sucrase-Isomaltase	Protein Coding	5.54	DISEASES inferred ¹⁵
15	ADAM8	ADAM Metallopeptidase Domain 8	Protein Coding	5.5	DISEASES inferred ¹⁵

Sources

Variations for Diabetic Autonomic Neuropathy

Sources

Expression for Diabetic Autonomic Neuropathy

Search GEO for disease gene expression data for Diabetic Autonomic Neuropathy.

Sources

Pathways for Diabetic Autonomic Neuropathy

Pathways related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	p70S6K Signaling ⁶³ Show member pathways mTOR Pathway ⁶³ Renin-Angiotensin Pathway ⁶³	12.24	REN NTF3 NGF INS ACE
2	Peptide hormone metabolism ⁶⁵ Show member pathways Glycoprotein hormones ⁶⁵ Insulin processing ⁶⁵ Metabolism of Angiotensinogen to Angiotensins ⁶⁵ Peptide hormone biosynthesis ⁶⁵ Synthesis, secretion, and deacylation of Ghrelin ⁶⁵	11.18	REN INS GCG ACE

Sources

GO Terms for Diabetic Autonomic Neuropathy

Cellular components related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.7	REN PPY NTF3 NGF MLN INS
2	extracellular space	GO:0005615	9.36	REN PPY NTF3 NGF INS GCG
3	endosome lumen	GO:0031904	9.16	NGF INS

Biological processes related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	G protein-coupled receptor signaling pathway	GO:0007186	9.8	PPY MLNR MLN INS GCG GAST
2	negative regulation of neuron apoptotic process	GO:0043524	9.61	NTF3 NGF ADAM8
3	nerve development	GO:0021675	9.4	NTF3 NGF
4	amyloid-beta metabolic process	GO:0050435	9.37	REN ACE
5	nerve growth factor signaling pathway	GO:0038180	9.26	NTF3 NGF
6	angiotensin maturation	GO:0002003	9.16	REN ACE
7	positive regulation of peptidyl-serine phosphorylation	GO:0033138	9.13	NTF3 NGF GCG
8	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	8.8	NTF3 INS EPO

Molecular functions related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	signaling receptor binding	GO:0005102	9.56	REN NTF3 NGF GCG
2	insulin-like growth factor receptor binding	GO:0005159	9.16	REN INS
3	hormone activity	GO:0005179	9.1	PPY MLN INS GCG GAST EPO
4	nerve growth factor receptor binding	GO:0005163	8.96	NTF3 NGF

Sources

Sources for Diabetic Autonomic Neuropathy

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia

Diabetic Autonomic Neuropathy

Aliases & Classifications for Diabetic Autonomic Neuropathy

MalaCards integrated aliases for Diabetic Autonomic Neuropathy:

Classifications:

External Ids:

Summaries for Diabetic Autonomic Neuropathy

Related Diseases for Diabetic Autonomic Neuropathy

Diseases related to Diabetic Autonomic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Diabetic Autonomic Neuropathy:

Symptoms & Phenotypes for Diabetic Autonomic Neuropathy

UMLS symptoms related to Diabetic Autonomic Neuropathy:

Drugs & Therapeutics for Diabetic Autonomic Neuropathy

Drugs for Diabetic Autonomic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Cochrane evidence based reviews: diabetic neuropathies

Genetic Tests for Diabetic Autonomic Neuropathy

Anatomical Context for Diabetic Autonomic Neuropathy

MalaCards organs/tissues related to Diabetic Autonomic Neuropathy:

Publications for Diabetic Autonomic Neuropathy

Articles related to Diabetic Autonomic Neuropathy:

Genes for Diabetic Autonomic Neuropathy

Genes related to Diabetic Autonomic Neuropathy (0 elite genes):

Variations for Diabetic Autonomic Neuropathy

Expression for Diabetic Autonomic Neuropathy

Pathways for Diabetic Autonomic Neuropathy

Pathways related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

GO Terms for Diabetic Autonomic Neuropathy

Cellular components related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

Biological processes related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

Molecular functions related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

Sources for Diabetic Autonomic Neuropathy

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :